Bonraybio Co., Ltd.
Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also offers consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes. In addition, the company provides X… Read more
Bonraybio Co., Ltd. (6955) - Total Assets
Latest total assets as of September 2025: NT$661.63 Million TWD
Based on the latest financial reports, Bonraybio Co., Ltd. (6955) holds total assets worth NT$661.63 Million TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bonraybio Co., Ltd. - Total Assets Trend (2021–2024)
This chart illustrates how Bonraybio Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bonraybio Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Bonraybio Co., Ltd.'s total assets of NT$661.63 Million consist of 92.7% current assets and 7.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 65.9% |
| Accounts Receivable | NT$18.21 Million | 2.9% |
| Inventory | NT$27.62 Million | 4.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Bonraybio Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bonraybio Co., Ltd.'s current assets represent 92.7% of total assets in 2024, an increase from 85.5% in 2021.
- Cash Position: Cash and equivalents constituted 65.9% of total assets in 2024, up from 26.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 4.4% of total assets.
Bonraybio Co., Ltd. Competitors by Total Assets
Key competitors of Bonraybio Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Bonraybio Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bonraybio Co., Ltd. generates 0.36x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Bonraybio Co., Ltd. generates $ 10.98 in net profit.
Bonraybio Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.02 | 9.17 | 9.17 |
| Quick Ratio | 12.11 | 8.53 | 8.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$551.47 Million | NT$ 282.40 Million | NT$ 282.40 Million |
Bonraybio Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Bonraybio Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.41 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 96.3% |
| Total Assets | NT$622.80 Million |
| Market Capitalization | $55.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bonraybio Co., Ltd.'s assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Bonraybio Co., Ltd.'s assets grew by 96.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bonraybio Co., Ltd. (2021–2024)
The table below shows the annual total assets of Bonraybio Co., Ltd. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$622.80 Million | +96.30% |
| 2023-12-31 | NT$317.26 Million | +13.30% |
| 2022-12-31 | NT$280.03 Million | +6.64% |
| 2021-12-31 | NT$262.61 Million | -- |